Metformin, Microbiome and Protection Against Colorectal Cancer

  title={Metformin, Microbiome and Protection Against Colorectal Cancer},
  author={G R Jones and Mark P. Molloy},
  journal={Digestive Diseases and Sciences},
  • G. JonesM. Molloy
  • Published 12 June 2020
  • Medicine, Biology
  • Digestive Diseases and Sciences
Metformin is widely used as a firstline therapy to improve insulin sensitivity in type 2 diabetes mellitus (T2DM) patients. This is achieved primarily through regulating AMP-activated protein kinase (AMPK)-dependent pathways leading to reduced hepatic gluconeogenesis and improved muscular uptake of glucose. Epidemiological studies first recognized a relationship with metformin use in T2DM patients and reduced colorectal cancer (CRC) risk. Thereafter, metformin has gained wide attention as a… 

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend

It was concluded that meetformin presents a unique opportunity for application against GC, but further clinical and mechanistic investigations are required to solidify the roles of metformin in GC.

Perspectives of metformin use in endometrial cancer and other gynaecological malignancies

This review presents the latest data on clinical use of metformin in endometrial cancer patients and potential underlying mechanisms of its activity, and some most important clinical information regarding met formin efficacy in other gynaecological malignancies, mainly breast and ovarian cancer.

Gut Microbiota: A Key Regulator in the Effects of Environmental Hazards on Modulates Insulin Resistance

  • Ruixue Huang
  • Biology
    Frontiers in Cellular and Infection Microbiology
  • 2021
Novel appreciation of the role of gut microbiota and environmental hazards in the insulin resistance would shed new light on insulin resistance and also promote the development of new research direction and new overcoming strategies for patients.

Therapeutic approaches to colorectal cancer via strategies based on modulation of gut microbiota

The role of Gut microbiota in the pathogenesis of CRC, the potential of gut microbiota as biomarkers for CRC, and therapeutic approaches to CRC based on the regulation of gut bacteria are discussed.

The Hormetic Effect of Metformin: “Less Is More”?

The effects of MTF on T2DM on the principal target organs, such as liver, gut, adipose tissue, endothelium, heart, and skeletal muscle, are described, indicating that all organs, except the gut, accumulate MTF in the micromolar range when administered in therapeutic doses.

CMAR_A_264032 8545..8554

It was concluded that meetformin presents a unique opportunity for application against GC, but further clinical and mechanistic investigations are required to solidify the roles of metformin in GC.

Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer

The mechanisms of action and resistance of immunotherapy and the types of immune checkpoint inhibitors (ICIs) as well as their correlation to gut microbiota are analyzed to present and analyze.

Correlation between Expression Profiles of Key Signaling Genes in Colorectal Cancer Samples from Type 2 Diabetic and Non-Diabetic Patients

In order to gain insight into diabetes-specific modulation of colon cancer signaling, gene expression patterns of more than five hundred genes encoding signaling proteins were analyzed from colonoscopic colorectal tumor samples of type 2 diabetic and non-diabetic patients.

A critical role of AMP‐activated protein kinase in regulating intestinal nutrient absorption, barrier function, and intestinal diseases

Current understanding regarding how 5′‐adenosine monophosphate‐activated protein kinase regulates intestinal nutrient absorption, barrier function, and intestinal diseases is summarized.

Targeting of the tumor immune microenvironment by metformin.

The purpose of this review is to explain the basic mechanisms for the interactions and communications between immunosuppressive, anti-tumoral, and cancer cells within TME.



Metformin as an Anticancer Agent.

Gut microbiota and intestinal FXR mediate the clinical benefits of metformin

It is concluded that metformin acts in part through a B. fragilis–GUDCA–intestinal FXR axis to improve metabolic dysfunction, including hyperglycemia, and improves the metabolic health of humans and mice.

Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.

  • Y. Saisho
  • Biology, Medicine
    Endocrine, metabolic & immune disorders drug targets
  • 2015
The basic and clinical evidence of the anti-inflammatory action of metformin is summarized and its clinical implication is discussed.

Metformin—mode of action and clinical implications for diabetes and cancer

The updated understanding of the antigluconeogenic action of met formin in the liver and the implications of the discoveries of metformin targets for the treatment of diabetes mellitus and cancer are discussed.

Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug

It is shown that metformin affected pathways with common biological functions in species from two different phyla, and many of the met formin-regulated genes in these species encoded metalloproteins or metal transporters, which provides support for the notion that altered gut microbiota mediates some of metformIn's antidiabetic effects.

Metformin and reduced risk of cancer in diabetic patients

It is hypothesised that metformin use in patients with type 2 diabetes may reduce their risk of cancer and tested this hypothesis using record linkage databases developed in Tayside, Scotland: a diabetes clinical information system (DARTS) and a database of dispensed prescriptions (MEMO).

The mechanisms of action of metformin

Physiologically, metformin has been shown to reduce hepatic glucose production, yet not all of its effects can be explained by this mechanism and there is increasing evidence of a key role for the gut.

Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data.

The available data on the capacity of antidiabetic biguanide drugs to prevent colorectal carcinogenesis and growth in vitro and in vivo in experimental models and clinical observations are presented.

Diet, microorganisms and their metabolites, and colon cancer

  • S. O'keefe
  • Biology, Medicine
    Nature Reviews Gastroenterology &Hepatology
  • 2016
The mechanisms behind microbial metabolite effects, which could be modified by diet to achieve the objective of preventing colorectal cancer in Western societies are discussed.

Metformin suppresses azoxymethane‐induced colorectal aberrant crypt foci by activating AMP‐activated protein kinase

Colorectal carcinogenesis in chemical carcinogen‐induced models is examined and metformin suppresses colonic epithelial proliferation via the inhibition of the mTOR pathway through the activation of AMPK.